从买不起到“带货”全球 宝安要成为高端医美的全球策源地？

Core Insights - The article highlights the significant advancements in China's medical aesthetics industry, particularly the achievements of a Shenzhen-based company in developing domestically produced ultrasound and radiofrequency medical devices that have received both NMPA and FDA certifications [1][2][3]. Group 1: Technological Breakthroughs - The first domestically produced ultrasound skin treatment device has received Class III certification, while the radiofrequency skin treatment device "Half Island Counterclockwise" is the first in China to obtain both NMPA and FDA approvals [1]. - The "Half Island Big Super Cannon" integrates various treatment handles and heads, enhancing treatment comfort and effectiveness, supported by clinical data showing an 82% effectiveness rate and 88% satisfaction rate from 204 cases [1]. - The radiofrequency microneedle device demonstrated a 96% effectiveness rate in scar improvement and a 98.75% patient satisfaction rate from 180 cases [1][2]. Group 2: Industry Evolution - Over the past 17 years, the company has transitioned from relying on foreign medical equipment to becoming a leader in the global medical aesthetics market, with a significant increase in R&D investment and patent applications [3]. - The company currently has a central R&D team of 180 members, with plans to increase the number of medical professionals to 65 by 2026, and has a notable share of global patent applications in the medical aesthetics sector [3]. - The company's ultrasound devices are now used in nearly 6,000 hospitals nationwide, and the radiofrequency microneedle has reached approximately 4,000 medical institutions, with user numbers projected to exceed 1 million by 2025 [3]. Group 3: Innovation Ecosystem - Shenzhen's innovation ecosystem has played a crucial role in the company's success, supported by policies, capital, and a rich clinical resource environment [4]. - The company has been recognized as a "national-level specialized and innovative small giant" and has received national-level intellectual property advantages, contributing to the growth of Shenzhen's high-end medical device industry [4]. - The company has published nearly 100 academic papers, with over 30 in SCI journals, and has participated in developing industry standards, promoting the standardization of the sector [4]. Group 4: Future Outlook - The year 2026 is anticipated to be pivotal for the medical aesthetics industry, focusing on compliance and high-quality development [7]. - The company emphasizes training for doctors and consumer education, with a rigorous certification system for device operation, ensuring standardized application of technology [7]. - The case reflects the broader trend of China's medical aesthetics industry evolving from imitation to innovation, aiming for international competitiveness [7].